On the recordJuly 27, 2021
Mr. Speaker, to that point, I believe that this problem does very much exist. Much of the research that is being conducted today must rely on private funding, and we cannot allow for that to be limited in its scope. If we only allow corporations or if we only allow well-moneyed interests and wealthy interests to have a monopoly on the ability to research these drugs, we are not acting and really fully using the resources of the public in order to determine the full benefits that could be possible. Mr. Speaker, I yield back the balance of my time.





